



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Polatuzumab vedotin

Cat. No.:	HY-132253
CAS No.:	1313206-42-6
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) ^[1] .								
In Vivo	<p>Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B-cell lymphoma WSU-DLCL2^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1, 3, 6, 12 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.; once</td> </tr> <tr> <td>Result:</td> <td>Showed dose-dependent tumour growth inhibition.</td> </tr> </table>	Animal Model:	SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2) ^[2]	Dosage:	0.3, 1, 3, 6, 12 mg/kg	Administration:	I.v.; once	Result:	Showed dose-dependent tumour growth inhibition.
Animal Model:	SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2) ^[2]								
Dosage:	0.3, 1, 3, 6, 12 mg/kg								
Administration:	I.v.; once								
Result:	Showed dose-dependent tumour growth inhibition.								

REFERENCES

[1]. Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. *Blood Adv.* 2021 Jul 13;5(13):2707-2716.

[2]. Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. *Br J Pharmacol.* 2019 Oct;176(19):3805-3818.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA